Blog
RSS FeedPosted by Michael Wonder on 25 May 2019
ICER comments on the FDA approval of Zolgensma for the treatment of spinal muscular atrophy
24 May 2019 - ICER’s update reflects the gene therapy’s new clinical data and FDA label. ...
Posted by Michael Wonder on 20 May 2019
ICER plans cloud-based tools to accelerate the use of value assessments in the US health care system
20 May 2019 - With a late 2019 launch target, ICER’s Evidence Compendium and Interactive Modeler will enable decision-makers within payers, ...
Posted by Michael Wonder on 02 May 2019
ICER seeks public input for 2020 value assessment framework
2 May 2019 - Accepting Open Input Through 10 June 2019. ...
Posted by Michael Wonder on 11 Apr 2019
The perils of value based pricing for prescription drugs
11 April 2019 - How do you determine the value, and the price, of life-saving medication? ...
Posted by Michael Wonder on 02 Apr 2019
When is the price of a drug unjust? The average lifetime earnings standard
1 April 2019 - The majority of Americans believe that lowering drug prices should be the top health care priority for ...
Posted by Michael Wonder on 12 Mar 2019
Overview of cost-effectiveness analysis
11 March 2019 - Health care decision makers, including patients, clinicians, hospitals, private health systems, and public payers (eg, Medicare), are ...
Posted by Michael Wonder on 23 Jan 2019
ICER launches international collaborative to develop new methods to guide value-based pricing of potential cures
23 January 2019 - NICE in the UK and CADTH in Canada among international agencies participating; public input on key methodological ...
Posted by Michael Wonder on 13 Dec 2018
ICER describes for patients and policy makers why the QALY is considered the best way to reward the care that improves patients’ lives
12 December 2018 - ICER reiterates its commitment to equality and will highlight measures of cost-effectiveness that value any extension of ...
Posted by Michael Wonder on 29 Nov 2018
Amgen cuts Repatha’s price by 60 percent. Will value-based pricing support value-based patient access?
28 November 2018 - Recently, Amgen announced a 60% reduction in the list price of its PCSK9 drug Repatha for patients ...
Posted by Michael Wonder on 06 Nov 2018
Should a drug’s value depend on the disease or population it treats? Insights from ICER’s value assessments
6 November 2018 - The ICER, a private, nonprofit organisation that evaluates the clinical and economic value of prescription drugs, ...
Posted by Michael Wonder on 27 Sep 2018
Paying for value: US state of play
27 September 2018 - Drug pricing in the US is a perennial topic, which is no surprise given the the ...
Posted by Michael Wonder on 01 Jun 2018
New analysis shows using ICER’s value assessments would limit access to life-saving medicines in Medicare Part B
31 May 2018 - 62 to 93% of Medicare Part B beneficiaries with serious, complex conditions could lose access to their ...
Posted by Michael Wonder on 09 May 2018
Evaluating and valuing drugs for rare conditions: no easy answers
9 May 2018 - We find ourselves in an era of unprecedented growth in the development and use of so-called “orphan” ...
Posted by Michael Wonder on 18 Mar 2018
Policy strategies for aligning price and value for brand-name pharmaceuticals
15 March 2018 - Systemic factors in the US health care system lead to greater pricing power for drug manufacturers than ...
Posted by Michael Wonder on 22 Feb 2018
A health economics approach to US value frameworks: serving the needs of decision-making
22 February 2018 - Value assessment is an integral component of decision making in health and is the focus of a ...